NCT02280993 2018-03-13Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Phase 1 Unknown72 enrolled